Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review

Novartis Unit’s Strategy Remains Unaltered As Parent Company Explores All Options

 
• By David Wallace
  
Richard Saynor
Richard Saynor says it is still ‘business as usual’ for Sandoz • Source: Sandoz
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business